Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 5-Fluorouracil (5-FU), 5-Fluorouracil
5 fluorouracil · 1 trial · 1 indication
PFS defined as time from date of randomization to date of first documentation of objective tumour progression or death due to any cause, whichever occurred first.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| 5 fluorouracil | DRUG | 400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days |
| irinotecan | DRUG | 180mg/m2 iv day 1 every 14 days |
| levo- leucovorin | DRUG | 200mg/m2 iv; day 1 every 14 days |
| sunitinib | DRUG | 37.5mg of blinded therapy every day for 28 days followed by 14 days of blinded therapy free period |
| placebo | DRUG | 37.5mg of blinded placebo therapy every day for 28 days followed by 14 days of blinded therapy free period |
Inclusion Criteria: * Confirmed (histologically or cytologically) colorectal adenocarcinoma with metastatic disease. * Not received previous therapy for metastatic colorectal disease but for whom FOLFIRI treatment is clinically indicated. * Adequate organ function defined by blood test. Exclusion ...
Top 20 of 77 competitors
5 fluorouracil, also known as 5-Fluorouracil (5-FU), is an oncology small molecule being studied for metastatic colorectal cancer and stomach neoplasms. It is part of combination chemotherapy regimens, such as FOLFIRI, in clinical trials for these advanced cancers.
5 fluorouracil is a small molecule antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis in rapidly dividing cancer cells. It is used in combination regimens for metastatic colorectal cancer and stomach neoplasms.
5 fluorouracil is being developed by Pfizer, Inc. (NYSE: PFE). The company sponsors clinical trials evaluating the drug in combination with other agents for metastatic colorectal cancer and stomach neoplasms.
5 fluorouracil is in Phase 3 clinical development for metastatic colorectal cancer. It is also being studied in a Phase 1 trial for stomach neoplasms. The drug is investigational and not yet approved for these indications.
5 fluorouracil is being studied in NCT00457691, a completed Phase 3 trial of FOLFIRI chemotherapy with or without sunitinib in 768 patients with metastatic colorectal cancer, and NCT00555672, a completed Phase 1 trial of sunitinib with cisplatin and 5-fluorouracil in 34 patients with advanced gastric cancer.
Yes, 5 fluorouracil is the same as 5-Fluorouracil (5-FU). It is also referred to as 5-Fluorouracil. These names are used interchangeably in clinical research and medical literature.